Day: April 25, 2024

Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May2023 financial key figures:        Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million)        Net result of CHF 54.8 million (2022: CHF -71.1 million)         Cash flow from operating activities of CHF 47.6 million (2022: CHF -29.8 million) Regulatory approvals in key territories – AGAMREE® (vamorolone) approved for Duchenne muscular dystrophy (DMD) treatment in the U.S., EU and UK, showcasing safety benefits over traditional corticosteroids Strategic partnership – licensing agreement signed with Catalyst...

Business update first quarter 2024 Regulated information 25 April 2024, 7 a.m. CET Business update Q1 2024 attached.AttachmentBusiness Update Q1 2024_EN

(2024-04-25) Kitron today reported strong underlying profitability in a challenging market. Cost initiatives are implemented to maintain operating margins in line with the company’s strategic target. Kitron’s revenue for the first quarter was EUR 173.9 million, compared to 190.6 million last year. There was strong growth within the Defence/Aerospace market sector, while other market sectors showed declines. First-quarter operating profit (EBIT) was EUR 10.6 million, compared to 17.3 million last year. EBITDA was EUR 15.2 million, compared to 21.4 million last year. Profits are impacted by restructuring charges of EUR 4.8 million. Profitability expressed as EBIT margin was 6.1 per cent, including the restructuring charges, compared to 9.1 per cent last year. Profitability adjusted for restructuring charges was 8.8 per cent. The order...

[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today’s event live 14:00 CEST Investor Q&A audio webcast Full details on our website …………. Vevey, April 25, 2024 Nestlé reports three-month sales for 2024Organic growth of 1.4%, with pricing of 3.4% and real internal growth (RIG) of -2.0%. Total reported sales were CHF 22.1 billion, a decrease of 5.9% (3M-2023: CHF 23.5 billion). Foreign exchange decreased sales by 6.7%. Net divestitures had a negative impact of 0.6%. Overall, organic sales growth for the Group was driven by Europe and emerging markets, with a negative impact from North America. Full-year 2024 outlook confirmed: we expect organic sales growth of around 4% and a moderate increase in the underlying trading...

PR No: C3254C STMicroelectronics Reports 2024 First Quarter Financial ResultsQ1 net revenues $3.47 billion; gross margin 41.7%; operating margin 15.9%; net income $513 million Q1 free cash flow1 $(134) million after Net Capex1 of $967 million Business outlook at mid-point: Q2 net revenues of $3.2 billion and gross margin of 40%Geneva, April 25, 2024 – STMicroelectronics N.V. (“ST”) (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, reported U.S. GAAP financial results for the first quarter ended March 30, 2024. This press release also contains non-U.S. GAAP measures (see Appendix for additional information). ST reported first quarter net revenues of $3.47 billion, gross margin of 41.7%, operating margin of 15.9%, and net income of $513 million or $0.54 diluted earnings per...

Paris, 25 April 2024, 7:00 a.m. PRESS RELEASE Eramet: Adjusted turnover of €761m in Q1 2024Adjusted turnover1 of €761m (-19%) reflecting, as expected, a strong negative price effect (-24%), while the positive volume effect is limited (+2%), penalised by the decline in SLN volumes soldGood operational performance of the Group’s main mining activities compared to the unfavourable comparison base of Q1 2023:+27% in manganese ore volumes sold from Gabon +52% in nickel ore volumes produced in Indonesia, but -17% in volumes sold, reflecting the absence of sales of low-grade saprolites over the quarter, whose commercialization permit for 2024 is under assessment by the Indonesian government +52% in zircon volumes and +36% in ilmenite2 sold from SenegalStrong decline in selling prices compared to Q1 2023Neutralization of SLN’s...

SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (“NPC”), and as a single agent for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The NDA is supported by results from...